BIO IPCC Conference Launches Next Week

Patently BIOtech

BIO’s IPCC Spring Conference is in San Diego next week, March 25-27.  Find this year’s line-up below and follow me on twitter at @rzwahlen for live tweeting of the panels.

Pre-Conference Workshop: Effecting and Managing Change  
Sponsored by: Foley & Lardner LLP

The panel will discuss lobbying and public messaging about IP. This workshop will provide an overview and illustrative anecdotes on how to lobby Congress and the administration on certain issues. and how to craft an effective public communications strategy (e.g. in the patent litigation context).

Workshop Faculty:

Scott Klug, Public Affairs Director, Foley & Lardner LLP
Carol Stratford, PhD, Counsel, KaloBios Pharmaceuticals, Inc.
Julie Chase, Chief Executive Officer, Chase Communications

Chairman’s Welcome & Breakfast
Sponsored by: Fenwick & West LLP

Speaker: Kevin H. Rhodes, Chief IP Counsel and President, 3M Innovative Properties Company

Session 1:  Seeds of Exhaustion: Analysis of Bowman v. Monsanto & the Shifting Doctrine of Patent Exhaustion 
Sponsored by: Fenwick & West LLP

This panel will discuss Bowman v Monsanto and its impact on the “first sale” or “patent exhaustion” doctrine. The panelists will discuss if an exception to the patent exhaustion doctrine should be created for self-replicating technologies and implications of such an exception. Self-replicating technologies include DNA sequences, virus strains, microorganisms and cell lines, among other technologies.

Moderator: Andrew Serafini, PhD, Partner, Fenwick & West LLP

Panelists:

Kevin Marks, Vice President & General Counsel, Roche Molecular Diagnostics
Mark P. Walters, Partner, Frommer Lawrence & Haug LLP
Paul Wolfson, Partner, WilmerHale
Mark Chapman, Partner, Carpmaels & Ransford

Session 2:  Any Port in a Storm – Section 271(e)(1) and the Continuing Debate Over Boundaries of Safe Harbor Exception     
Sponsored by: Fenwick & West LLP

The U.S. Supreme Court recently refused to review the Federal Circuit’s decision in Classen v. Biogen IDEC excluding post-approval regulatory activity from the safe harbor established by 35 U.S.C. § 271(e)(1).  This panel will discuss the scope of the § 271(e)(1) safe harbor in light of the Supreme Court’s denial of certioriari, as well as the Federal Circuit’s subsequent decision in Momenta v. Amphastar limiting the reach of Classen.

Moderator: David Tellekson, Partner, Fenwick & West LLP

Panelists:
Mark Sandbaken, PhD, Executive Director of Intellectual Property, Seattle Genetics
Paul Fehlner, Global Head of Pharma Intellectual Property, Novartis Pharma AG
Jeff Rennecker, Senior Corporate Counsel, Pfizer Inc.

Keynote Luncheon
Sponsored by: Foley Hoag LLP

Speaker: The Honorable Marilyn L. Huff, District Judge, U.S. District Court for the Southern District of California

Session 3:  The Method Patent Roller-coaster  
Sponsored by: Foley Hoag LLP

In the Akamai and McKesson cases, the Federal Circuit addressed divided infringement and found itself closely divided. The law on direct infringement remains up for grabs, and the court’s en banc opinion may not be the last word on indirect infringement. Method patents also present unique challenge under sections 101, 112, 271(e)(1), 271(f), and 271 (g). This session will discuss problems and solutions in light of the evolving law on method patents, offering perspectives from a trial lawyer, a patent prosecutor, and in-house patent counsel.

Moderator: Don Ware, Partner, Foley Hoag LLP

Panelists:
Yuko Soneoka, PhD, Senior Corporate Counsel, IP & Director of IP, Genomic Health
Bernard Greenspan, Director, Intellectual Property, Prometheus Laboratories

Session 4: Patent Opinions Revisited: New Risks, New Rewards 
Sponsored by: Foley Hoag LLP

The decisions in In re Seagate, Global Tech, and C.R. Bard have created new standards and procedures — with inherent risks and potential rewards — to justify reliance on freedom-to-operate opinions at trial. This panel will address best practices for obtaining and relying upon opinions of counsel from the perspectives of a trial lawyer, in-house patent counsel, and a jury consultant.

Moderator: Barbara Fiacco, Partner, Foley Hoag LLP

Panelists:
Dan Gallipeau, PhD, President, Dispute Dynamics, Inc.
William R. Majarian, Vice President, Global Patents, GlaxoSmithKline

Keynote Breakfast    
Sponsored by: Alston & Bird LLP

Speaker: Jeffrey A. Lefstin, Professor of Law, University of California, San Francisco, Hastings College of the Law

The Supreme Court’s upcoming Myriad case will do more than decide whether genes are patent-eligible; it may deicde to what extent any patent based on scientific discovery remains patent-eligible.  Professor Jeffrey Lefstin provides a historical perspective, suggesting that past practice may inform the Court on which analytical framework suggested by Mayo v. Prometheus should govern the patent-eligibility inquiry.

Session 5:  The AIA and APA: Oversight of Patents and the Agency That Grants Them  
Sponsored by: Alston & Bird LLP

As the AIA has empowered the PTO with conducting new procedures, so the PTO has itself been subject to increasing scrutiny for acting outside its statutory authority.  This panel will discuss real-life experience with the new PTO post grant procedures since their implementation.  The panel will also consider the case of Excela Pharma v. Kappos, in which the PTO’s authority is under attack.  This case challenges the PTO’s authority to revive unintentionally abandoned applications.  The Federal Circuit rejected such a challenge five years ago in patent infringement litigation.  But the new challenge is brought via the APA against the PTO Commissioner, and once again places the validity of thousands of patents in question.

Moderator: Romy Celli, Partner, Alston & Bird LLP

Panelists:
Joe Liebeschuetz, PhD, Partner, Alston & Bird LLP
Nancy Linck, Of Counsel, Rothwell, Figg, Ernst & Manbeck

Session 6: Case Law Updates  
Sponsored by: Alston & Bird LLP

This panel will provide an update on recent patent cases including how the lower courts have dealt with guidance from the Supreme Court and Federal Circuit. Particularly, the panel will focus on cases dealing with claim construction, inequitable conduct, obviousness, and patentability, and provide perspectives from in-house and outside counsel.

Moderator: Jitty Malik, PhD, Partner, Alston & Bird LLP

Panelists:
Phil Makrogiannis, Division Lead IP Counsel, Life Technologies Inc.
John W. Cox, PhD, Counsel, Alston & Bird LLP
Timothy O’Sullivan, Vice President of Business Development, Novan, Inc.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>